London, United Kingdom
London, United Kingdom

Time filter

Source Type

Patent
CANCER RESEARCH TECHNOLOGY Ltd and Institute Of Cancer Research Royal Cancer Hospital The | Date: 2016-09-01

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as IP compounds), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (mutant RAS cancer). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.


The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.


Patent
Astex, The Institute Of Cancer Research Royal Cancer Hospital and Cancer Research Technology Ltd | Date: 2016-01-29

The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R^(1 )and NR^(2)R^(3 )and a maximum chain length of 4 atoms extending between E and NR^(2)R^(3), wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom with respect to the NR^(2)R^(3 )group and provided that the oxo group when present is located at a carbon atom with respect to the NR^(2)R^(3 )group;E is a monocyclic or bicyclic carbocyclic or heterocyclic group;R^(1 )is an aryl or heteroaryl group; andR^(2), R^(3), R^(4 )and R^(5 )are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.


Patent
Tel Aviv University, Technion Research And Development Foundation Ltd. and CANCER RESEARCH TECHNOLOGY Ltd | Date: 2016-03-31

A method for creating a metabolic map of metabolic reactions by selecting metabolic reactions active in cancer cells. A core set of metabolic reactions occurring in the cancer cells is designated. For each permutation, whether inhibition of the k-th non-core reaction together with inhibition of all previously deleted non-core reactions results in inhibition of any of the core reactions or results in inhibition of the flux of biomass metabolites to biomass is determined. If inhibition of the k-th non-core reaction and inhibition of all previously deleted non-core reactions does not result in inhibition of any core reactions and does not result in inhibition of the flux of biomass metabolites to biomass, then the k-th non-core reaction is deleted from the set of non-core reactions. The number of permutations for which the k-th non-core reaction is not deleted is determined and a metabolic map is then created based on that number.


The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.


Patent
CANCER RESEARCH TECHNOLOGY Ltd | Date: 2016-05-10

A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.


Patent
Cancer Research Technology Ltd | Date: 2016-04-06

The present invention relates to compounds of formula I wherein R_(1), R_(4), Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.


Patent
Cancer Research Technology Ltd | Date: 2016-04-06

The present invention relates to compounds of formula I wherein R_(1), R_(4), Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.


Patent
Cancer Research Technology Ltd | Date: 2016-06-24

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.


Patent
Cancer Research Technology Ltd | Date: 2016-03-14

The present invention relates to compounds of formula II wherein X, Y, R_(2), R_(3), R_(4 )and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Loading Cancer Research Technology Ltd collaborators
Loading Cancer Research Technology Ltd collaborators